Jump To Section:

Identification Taxonomy Ontology Physical properties Spectra Biological properties Concentrations Links References enzymes (3)transporters (2) Show 5 proteins XML

enzymes (3)transporters (2) Show 5 proteins

Record Information

Version

5.0

Status

Expected but not Quantified

Creation Date

2012-09-06 15:16:49 UTC

Update Date

2022-03-07 02:51:37 UTC

HMDB ID

HMDB0014434

Secondary Accession Numbers

HMDB14434

Metabolite Identification

Common Name

Atomoxetine

Description

Atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. This chemical is manufactured and marketed under the brand name Strattera; by Eli Lilly and Company and as a generic Attentin by Torrent Pharmaceuticals. There is currently no generic available within the United States due to patent restrictions. [Wikipedia ]

Structure

MOL 3D MOL SDF 3D SDF PDB 3D PDB SMILES InChI

HMDB0014434
     RDKit          3D
Atomoxetine
 40 41  0  0  0  0  0  0  0  0999 V2000
   -3.5090   -2.5440    0.7809 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8148   -2.2423    2.0217 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0776   -0.9825    1.8982 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9415   -1.2042    0.9206 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1247    0.0543    0.7183 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.8910   -0.2776   -0.2008 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.2261   -0.0232   -0.0821 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8272    0.6204    0.9712 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2001    0.8270    0.9885 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9707    0.3814   -0.0633 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4009   -0.2687   -1.1368 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0343   -0.4624   -1.1316 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4183   -1.1742   -2.3024 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9796    1.0652   -0.0033 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3858    0.8778   -1.3010 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1679    1.8290   -1.9220 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5749    2.9950   -1.2840 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1535    3.1619    0.0222 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3716    2.2120    0.6441 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3183   -3.2605    0.9544 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8247   -2.9235   -0.0002 H   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9540   -1.5947    0.4014 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1469   -3.0217    2.2355 H   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7202   -0.7410    2.9099 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7986   -0.2400    1.4928 H   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3289   -1.5422   -0.0437 H   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2958   -1.9963    1.3320 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.2151    0.5147    1.6432 H   0  0  0  0  0  0  0  0  0  0  0  0
    2.1886    0.9549    1.7769 H   0  0  0  0  0  0  0  0  0  0  0  0
    4.6404    1.3435    1.8463 H   0  0  0  0  0  0  0  0  0  0  0  0
    6.0495    0.5396   -0.0574 H   0  0  0  0  0  0  0  0  0  0  0  0
    5.0238   -0.6207   -1.9729 H   0  0  0  0  0  0  0  0  0  0  0  0
    1.3949   -1.5278   -2.0122 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.0063   -2.1011   -2.4824 H   0  0  0  0  0  0  0  0  0  0  0  0
    2.3351   -0.5397   -3.1916 H   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0967   -0.0174   -1.8528 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5062    1.7083   -2.9503 H   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1928    3.7341   -1.7914 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4521    4.0632    0.5559 H   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0865    2.4232    1.6683 H   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
  5 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 12  7  1  0
 19 14  1  0
  1 20  1  0
  1 21  1  0
  1 22  1  0
  2 23  1  0
  3 24  1  0
  3 25  1  0
  4 26  1  0
  4 27  1  0
  5 28  1  1
  8 29  1  0
  9 30  1  0
 10 31  1  0
 11 32  1  0
 13 33  1  0
 13 34  1  0
 13 35  1  0
 15 36  1  0
 16 37  1  0
 17 38  1  0
 18 39  1  0
 19 40  1  0
M  END

54841
  Mrv0541 02231214342D          

 19 20  0  0  1  0            999 V2000
    3.0790   -0.2063    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    5.9370   -0.2063    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.7935    0.2063    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0
    4.5080   -0.2063    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7935    1.0313    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.2224    0.2063    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0790   -1.0313    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5080    1.4438    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0790    1.4438    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3645   -1.4438    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5080    2.2688    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0790    2.2688    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7935   -1.4438    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7935    2.6813    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6515    0.2063    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3645   -2.2688    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6500   -1.0313    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7935   -2.2688    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0790   -2.6813    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  3  1  1  1  0  0  0
  1  7  1  0  0  0  0
  2  6  1  0  0  0  0
  2 15  1  0  0  0  0
  3  4  1  0  0  0  0
  3  5  1  0  0  0  0
  4  6  1  0  0  0  0
  5  8  2  0  0  0  0
  5  9  1  0  0  0  0
  7 10  1  0  0  0  0
  7 13  2  0  0  0  0
  8 11  1  0  0  0  0
  9 12  2  0  0  0  0
 10 16  2  0  0  0  0
 10 17  1  0  0  0  0
 11 14  2  0  0  0  0
 12 14  1  0  0  0  0
 13 18  1  0  0  0  0
 16 19  1  0  0  0  0
 18 19  2  0  0  0  0
M  END
> <DATABASE_ID>
HMDB0014434

> <DATABASE_NAME>
hmdb

> <SMILES>
CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1

> <INCHI_IDENTIFIER>
InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1

> <INCHI_KEY>
VHGCDTVCOLNTBX-QGZVFWFLSA-N

> <FORMULA>
C17H21NO

> <MOLECULAR_WEIGHT>
255.3547

> <EXACT_MASS>
255.162314299

> <JCHEM_ACCEPTOR_COUNT>
2

> <JCHEM_AVERAGE_POLARIZABILITY>
29.793043055003068

> <JCHEM_BIOAVAILABILITY>
1

> <JCHEM_DONOR_COUNT>
1

> <JCHEM_FORMAL_CHARGE>
0

> <JCHEM_GHOSE_FILTER>
1

> <JCHEM_IUPAC>
methyl[(3R)-3-(2-methylphenoxy)-3-phenylpropyl]amine

> <ALOGPS_LOGP>
3.95

> <JCHEM_LOGP>
3.8087924510000004

> <ALOGPS_LOGS>
-4.82

> <JCHEM_MDDR_LIKE_RULE>
0

> <JCHEM_NUMBER_OF_RINGS>
2

> <JCHEM_PHYSIOLOGICAL_CHARGE>
1

> <JCHEM_PKA_STRONGEST_BASIC>
9.803139237207063

> <JCHEM_POLAR_SURFACE_AREA>
21.259999999999998

> <JCHEM_REFRACTIVITY>
79.43500000000002

> <JCHEM_ROTATABLE_BOND_COUNT>
6

> <JCHEM_RULE_OF_FIVE>
1

> <ALOGPS_SOLUBILITY>
3.90e-03 g/l

> <JCHEM_TRADITIONAL_IUPAC>
atomoxetine

> <JCHEM_VEBER_RULE>
1

$$$$

HMDB0014434
     RDKit          3D
Atomoxetine
 40 41  0  0  0  0  0  0  0  0999 V2000
   -3.5090   -2.5440    0.7809 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8148   -2.2423    2.0217 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0776   -0.9825    1.8982 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9415   -1.2042    0.9206 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1247    0.0543    0.7183 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.8910   -0.2776   -0.2008 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.2261   -0.0232   -0.0821 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8272    0.6204    0.9712 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2001    0.8270    0.9885 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9707    0.3814   -0.0633 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4009   -0.2687   -1.1368 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0343   -0.4624   -1.1316 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4183   -1.1742   -2.3024 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9796    1.0652   -0.0033 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3858    0.8778   -1.3010 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1679    1.8290   -1.9220 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5749    2.9950   -1.2840 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1535    3.1619    0.0222 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3716    2.2120    0.6441 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3183   -3.2605    0.9544 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8247   -2.9235   -0.0002 H   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9540   -1.5947    0.4014 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1469   -3.0217    2.2355 H   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7202   -0.7410    2.9099 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7986   -0.2400    1.4928 H   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3289   -1.5422   -0.0437 H   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2958   -1.9963    1.3320 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.2151    0.5147    1.6432 H   0  0  0  0  0  0  0  0  0  0  0  0
    2.1886    0.9549    1.7769 H   0  0  0  0  0  0  0  0  0  0  0  0
    4.6404    1.3435    1.8463 H   0  0  0  0  0  0  0  0  0  0  0  0
    6.0495    0.5396   -0.0574 H   0  0  0  0  0  0  0  0  0  0  0  0
    5.0238   -0.6207   -1.9729 H   0  0  0  0  0  0  0  0  0  0  0  0
    1.3949   -1.5278   -2.0122 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.0063   -2.1011   -2.4824 H   0  0  0  0  0  0  0  0  0  0  0  0
    2.3351   -0.5397   -3.1916 H   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0967   -0.0174   -1.8528 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5062    1.7083   -2.9503 H   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1928    3.7341   -1.7914 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4521    4.0632    0.5559 H   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0865    2.4232    1.6683 H   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
  5 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 12  7  1  0
 19 14  1  0
  1 20  1  0
  1 21  1  0
  1 22  1  0
  2 23  1  0
  3 24  1  0
  3 25  1  0
  4 26  1  0
  4 27  1  0
  5 28  1  1
  8 29  1  0
  9 30  1  0
 10 31  1  0
 11 32  1  0
 13 33  1  0
 13 34  1  0
 13 35  1  0
 15 36  1  0
 16 37  1  0
 17 38  1  0
 18 39  1  0
 19 40  1  0
M  END

HEADER    PROTEIN                                 23-FEB-12   NONE
TITLE     NULL                                                        
COMPND    MOLECULE: 54841                                             
SOURCE    NULL                                                        
KEYWDS    NULL                                                        
EXPDTA    NULL                                                        
AUTHOR    Marvin                                                      
REVDAT   1   23-FEB-12         0                                  
HETATM    1  O   UNK     0       5.747  -0.385   0.000  0.00  0.00           O+0
HETATM    2  N   UNK     0      11.082  -0.385   0.000  0.00  0.00           N+0
HETATM    3  C   UNK     0       7.081   0.385   0.000  0.00  0.00           C+0
HETATM    4  C   UNK     0       8.415  -0.385   0.000  0.00  0.00           C+0
HETATM    5  C   UNK     0       7.081   1.925   0.000  0.00  0.00           C+0
HETATM    6  C   UNK     0       9.748   0.385   0.000  0.00  0.00           C+0
HETATM    7  C   UNK     0       5.747  -1.925   0.000  0.00  0.00           C+0
HETATM    8  C   UNK     0       8.415   2.695   0.000  0.00  0.00           C+0
HETATM    9  C   UNK     0       5.747   2.695   0.000  0.00  0.00           C+0
HETATM   10  C   UNK     0       4.414  -2.695   0.000  0.00  0.00           C+0
HETATM   11  C   UNK     0       8.415   4.235   0.000  0.00  0.00           C+0
HETATM   12  C   UNK     0       5.747   4.235   0.000  0.00  0.00           C+0
HETATM   13  C   UNK     0       7.081  -2.695   0.000  0.00  0.00           C+0
HETATM   14  C   UNK     0       7.081   5.005   0.000  0.00  0.00           C+0
HETATM   15  C   UNK     0      12.416   0.385   0.000  0.00  0.00           C+0
HETATM   16  C   UNK     0       4.414  -4.235   0.000  0.00  0.00           C+0
HETATM   17  C   UNK     0       3.080  -1.925   0.000  0.00  0.00           C+0
HETATM   18  C   UNK     0       7.081  -4.235   0.000  0.00  0.00           C+0
HETATM   19  C   UNK     0       5.747  -5.005   0.000  0.00  0.00           C+0
CONECT    1    3    7                                                       
CONECT    2    6   15                                                       
CONECT    3    1    4    5                                                  
CONECT    4    3    6                                                       
CONECT    5    3    8    9                                                  
CONECT    6    2    4                                                       
CONECT    7    1   10   13                                                  
CONECT    8    5   11                                                       
CONECT    9    5   12                                                       
CONECT   10    7   16   17                                                  
CONECT   11    8   14                                                       
CONECT   12    9   14                                                       
CONECT   13    7   18                                                       
CONECT   14   11   12                                                       
CONECT   15    2                                                            
CONECT   16   10   19                                                       
CONECT   17   10                                                            
CONECT   18   13   19                                                       
CONECT   19   16   18                                                       
MASTER        0    0    0    0    0    0    0    0   19    0   40    0
END

COMPND    HMDB0014434
HETATM    1  C1  UNL     1      -3.509  -2.544   0.781  1.00  0.00           C  
HETATM    2  N1  UNL     1      -2.815  -2.242   2.022  1.00  0.00           N  
HETATM    3  C2  UNL     1      -2.078  -0.982   1.898  1.00  0.00           C  
HETATM    4  C3  UNL     1      -0.941  -1.204   0.921  1.00  0.00           C  
HETATM    5  C4  UNL     1      -0.125   0.054   0.718  1.00  0.00           C  
HETATM    6  O1  UNL     1       0.891  -0.278  -0.201  1.00  0.00           O  
HETATM    7  C5  UNL     1       2.226  -0.023  -0.082  1.00  0.00           C  
HETATM    8  C6  UNL     1       2.827   0.620   0.971  1.00  0.00           C  
HETATM    9  C7  UNL     1       4.200   0.827   0.988  1.00  0.00           C  
HETATM   10  C8  UNL     1       4.971   0.381  -0.063  1.00  0.00           C  
HETATM   11  C9  UNL     1       4.401  -0.269  -1.137  1.00  0.00           C  
HETATM   12  C10 UNL     1       3.034  -0.462  -1.132  1.00  0.00           C  
HETATM   13  C11 UNL     1       2.418  -1.174  -2.302  1.00  0.00           C  
HETATM   14  C12 UNL     1      -0.980   1.065  -0.003  1.00  0.00           C  
HETATM   15  C13 UNL     1      -1.386   0.878  -1.301  1.00  0.00           C  
HETATM   16  C14 UNL     1      -2.168   1.829  -1.922  1.00  0.00           C  
HETATM   17  C15 UNL     1      -2.575   2.995  -1.284  1.00  0.00           C  
HETATM   18  C16 UNL     1      -2.153   3.162   0.022  1.00  0.00           C  
HETATM   19  C17 UNL     1      -1.372   2.212   0.644  1.00  0.00           C  
HETATM   20  H1  UNL     1      -4.318  -3.261   0.954  1.00  0.00           H  
HETATM   21  H2  UNL     1      -2.825  -2.923  -0.000  1.00  0.00           H  
HETATM   22  H3  UNL     1      -3.954  -1.595   0.401  1.00  0.00           H  
HETATM   23  H4  UNL     1      -2.147  -3.022   2.236  1.00  0.00           H  
HETATM   24  H5  UNL     1      -1.720  -0.741   2.910  1.00  0.00           H  
HETATM   25  H6  UNL     1      -2.799  -0.240   1.493  1.00  0.00           H  
HETATM   26  H7  UNL     1      -1.329  -1.542  -0.044  1.00  0.00           H  
HETATM   27  H8  UNL     1      -0.296  -1.996   1.332  1.00  0.00           H  
HETATM   28  H9  UNL     1       0.215   0.515   1.643  1.00  0.00           H  
HETATM   29  H10 UNL     1       2.189   0.955   1.777  1.00  0.00           H  
HETATM   30  H11 UNL     1       4.640   1.343   1.846  1.00  0.00           H  
HETATM   31  H12 UNL     1       6.049   0.540  -0.057  1.00  0.00           H  
HETATM   32  H13 UNL     1       5.024  -0.621  -1.973  1.00  0.00           H  
HETATM   33  H14 UNL     1       1.395  -1.528  -2.012  1.00  0.00           H  
HETATM   34  H15 UNL     1       3.006  -2.101  -2.482  1.00  0.00           H  
HETATM   35  H16 UNL     1       2.335  -0.540  -3.192  1.00  0.00           H  
HETATM   36  H17 UNL     1      -1.097  -0.017  -1.853  1.00  0.00           H  
HETATM   37  H18 UNL     1      -2.506   1.708  -2.950  1.00  0.00           H  
HETATM   38  H19 UNL     1      -3.193   3.734  -1.791  1.00  0.00           H  
HETATM   39  H20 UNL     1      -2.452   4.063   0.556  1.00  0.00           H  
HETATM   40  H21 UNL     1      -1.086   2.423   1.668  1.00  0.00           H  
CONECT    1    2   20   21   22
CONECT    2    3   23
CONECT    3    4   24   25
CONECT    4    5   26   27
CONECT    5    6   14   28
CONECT    6    7
CONECT    7    8    8   12
CONECT    8    9   29
CONECT    9   10   10   30
CONECT   10   11   31
CONECT   11   12   12   32
CONECT   12   13
CONECT   13   33   34   35
CONECT   14   15   15   19
CONECT   15   16   36
CONECT   16   17   17   37
CONECT   17   18   38
CONECT   18   19   19   39
CONECT   19   40
END

HMDB0014434
     RDKit          3D
Atomoxetine
 40 41  0  0  0  0  0  0  0  0999 V2000
   -3.5090   -2.5440    0.7809 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8148   -2.2423    2.0217 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0776   -0.9825    1.8982 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9415   -1.2042    0.9206 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.1247    0.0543    0.7183 C   0  0  1  0  0  0  0  0  0  0  0  0
    0.8910   -0.2776   -0.2008 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.2261   -0.0232   -0.0821 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.8272    0.6204    0.9712 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2001    0.8270    0.9885 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.9707    0.3814   -0.0633 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4009   -0.2687   -1.1368 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0343   -0.4624   -1.1316 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4183   -1.1742   -2.3024 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.9796    1.0652   -0.0033 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3858    0.8778   -1.3010 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1679    1.8290   -1.9220 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5749    2.9950   -1.2840 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1535    3.1619    0.0222 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3716    2.2120    0.6441 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3183   -3.2605    0.9544 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8247   -2.9235   -0.0002 H   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9540   -1.5947    0.4014 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.1469   -3.0217    2.2355 H   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7202   -0.7410    2.9099 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.7986   -0.2400    1.4928 H   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3289   -1.5422   -0.0437 H   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2958   -1.9963    1.3320 H   0  0  0  0  0  0  0  0  0  0  0  0
    0.2151    0.5147    1.6432 H   0  0  0  0  0  0  0  0  0  0  0  0
    2.1886    0.9549    1.7769 H   0  0  0  0  0  0  0  0  0  0  0  0
    4.6404    1.3435    1.8463 H   0  0  0  0  0  0  0  0  0  0  0  0
    6.0495    0.5396   -0.0574 H   0  0  0  0  0  0  0  0  0  0  0  0
    5.0238   -0.6207   -1.9729 H   0  0  0  0  0  0  0  0  0  0  0  0
    1.3949   -1.5278   -2.0122 H   0  0  0  0  0  0  0  0  0  0  0  0
    3.0063   -2.1011   -2.4824 H   0  0  0  0  0  0  0  0  0  0  0  0
    2.3351   -0.5397   -3.1916 H   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0967   -0.0174   -1.8528 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5062    1.7083   -2.9503 H   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1928    3.7341   -1.7914 H   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4521    4.0632    0.5559 H   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0865    2.4232    1.6683 H   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
  5 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 18 19  2  0
 12  7  1  0
 19 14  1  0
  1 20  1  0
  1 21  1  0
  1 22  1  0
  2 23  1  0
  3 24  1  0
  3 25  1  0
  4 26  1  0
  4 27  1  0
  5 28  1  1
  8 29  1  0
  9 30  1  0
 10 31  1  0
 11 32  1  0
 13 33  1  0
 13 34  1  0
 13 35  1  0
 15 36  1  0
 16 37  1  0
 17 38  1  0
 18 39  1  0
 19 40  1  0
M  END

View in JSmol View Stereo Labels

Synonyms

Value	Source
(-)-Tomoxetine	ChEBI
Tomoxetina	ChEBI
Tomoxetine	ChEBI
Tomoxetinum	ChEBI
Tomoxetine hydrochloride, (-)-isomer	HMDB
HCL, Atomoxetine	HMDB
Hydrochloride, atomoxetine	HMDB
Strattera	HMDB
Atomoxetine hydrochloride	HMDB
Tomoxetine hydrochloride, (+-)-isomer	HMDB
Atomoxetine HCL	HMDB
N-Methyl-gamma-(2-methylphenoxy)benzenepropanamine hydrochloride	HMDB
Tomoxetine hydrochloride, (+)-isomer - T351671	HMDB

Chemical Formula

C₁₇H₂₁NO

Average Molecular Weight

255.3547

Monoisotopic Molecular Weight

255.162314299

IUPAC Name

methyl[(3R)-3-(2-methylphenoxy)-3-phenylpropyl]amine

Traditional Name

atomoxetine

CAS Registry Number

82248-59-7

SMILES

CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1

InChI Identifier

InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1

InChI Key

VHGCDTVCOLNTBX-QGZVFWFLSA-N

Chemical Taxonomy

Description

Belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.

Kingdom

Organic compounds

Super Class

Benzenoids

Class

Phenol ethers

Sub Class

Not Available

Direct Parent

Phenol ethers

Alternative Parents

Substituents

Phenoxy compound
Phenol ether
Alkyl aryl ether
Toluene
Aralkylamine
Monocyclic benzene moiety
Secondary aliphatic amine
Ether
Secondary amine
Organooxygen compound
Organonitrogen compound
Amine
Organic nitrogen compound
Organic oxygen compound
Organopnictogen compound
Hydrocarbon derivative
Aromatic homomonocyclic compound

Molecular Framework

Aromatic homomonocyclic compounds

External Descriptors

aromatic ether (CHEBI:127342 )
secondary amino compound (CHEBI:127342 )
toluenes (CHEBI:127342 )

Ontology

Not Available

Urine (PMID: 21059682)

Non-excretory biofluid

Blood (PMID: 21059682)

Cellular substructure

Membrane (HMDB: HMDB0014434)

Process

Not Available

Role

Industrial application

Manufacturing industry

Material processing agent

Coloring agent

Fluorescent agent

antidepressant (HMDB: HMDB0014434)

adrenergic uptake inhibitor (HMDB: HMDB0014434)

Physical Properties

State

Solid

Experimental Molecular Properties

Property	Value	Reference
Melting Point	Not Available	Not Available
Boiling Point	Not Available	Not Available
Water Solubility	0.0039 g/L	Not Available
LogP	3.9	Not Available

Experimental Chromatographic Properties

Experimental Collision Cross Sections

Adduct Type	Data Source	CCS Value (Å²)	Reference
[M+H]+	CBM	164.2	30932474

Predicted Molecular Properties

Property	Value	Source
Water Solubility	0.0039 g/L	ALOGPS
logP	3.95	ALOGPS
logP	3.81	ChemAxon
logS	-4.8	ALOGPS
pKa (Strongest Basic)	9.8	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	2	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	21.26 Å²	ChemAxon
Rotatable Bond Count	6	ChemAxon
Refractivity	79.44 m³·mol⁻¹	ChemAxon
Polarizability	29.79 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	Yes	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted Chromatographic Properties

Predicted Collision Cross Sections

Predictor	Adduct Type	CCS Value (Å²)	Reference
DarkChem	[M+H]+	162.71	31661259
DarkChem	[M-H]-	160.915	31661259
DeepCCS	[M+H]+	164.178	30932474
DeepCCS	[M-H]-	161.82	30932474
DeepCCS	[M-2H]-	194.707	30932474
DeepCCS	[M+Na]+	170.271	30932474
AllCCS	[M+H]+	160.7	32859911
AllCCS	[M+H-H2O]+	156.9	32859911
AllCCS	[M+NH4]+	164.3	32859911
AllCCS	[M+Na]+	165.3	32859911
AllCCS	[M-H]-	166.8	32859911
AllCCS	[M+Na-2H]-	166.7	32859911
AllCCS	[M+HCOO]-	166.7	32859911

Predicted Kovats Retention Indices

Underivatized

Metabolite	SMILES	Kovats RI Value	Column Type	Reference
Atomoxetine	CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1	2492.0	Standard polar	33892256
Atomoxetine	CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1	1962.7	Standard non polar	33892256
Atomoxetine	CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1	1970.9	Semi standard non polar	33892256

Derivatized

Derivative Name / Structure	SMILES	Kovats RI Value	Column Type	Reference
Atomoxetine,1TMS,isomer #1	CC1=CC=CC=C1O[C@H](CCN(C)[Si](C)(C)C)C1=CC=CC=C1	2205.6	Semi standard non polar	33892256
Atomoxetine,1TMS,isomer #1	CC1=CC=CC=C1O[C@H](CCN(C)[Si](C)(C)C)C1=CC=CC=C1	2189.1	Standard non polar	33892256
Atomoxetine,1TMS,isomer #1	CC1=CC=CC=C1O[C@H](CCN(C)[Si](C)(C)C)C1=CC=CC=C1	2692.7	Standard polar	33892256
Atomoxetine,1TBDMS,isomer #1	CC1=CC=CC=C1O[C@H](CCN(C)[Si](C)(C)C(C)(C)C)C1=CC=CC=C1	2456.7	Semi standard non polar	33892256
Atomoxetine,1TBDMS,isomer #1	CC1=CC=CC=C1O[C@H](CCN(C)[Si](C)(C)C(C)(C)C)C1=CC=CC=C1	2372.8	Standard non polar	33892256
Atomoxetine,1TBDMS,isomer #1	CC1=CC=CC=C1O[C@H](CCN(C)[Si](C)(C)C(C)(C)C)C1=CC=CC=C1	2797.6	Standard polar	33892256

Spectra

GC-MS Spectra

Spectrum Type	Description	Splash Key	Deposition Date	Source	View
Predicted GC-MS	Predicted GC-MS Spectrum - Atomoxetine GC-MS (Non-derivatized) - 70eV, Positive	splash10-0007-9510000000-b436c1286414de57d10e	2017-09-01	Wishart Lab	View Spectrum
Predicted GC-MS	Predicted GC-MS Spectrum - Atomoxetine GC-MS (Non-derivatized) - 70eV, Positive	Not Available	2021-10-12	Wishart Lab	View Spectrum

MS/MS Spectra

Spectrum Type	Description	Splash Key	Deposition Date	Source	View
Experimental LC-MS/MS	LC-MS/MS Spectrum - Atomoxetine LC-ESI-qTof , Positive-QTOF	splash10-0a4i-0690000000-494128ae0f3b90b415b3	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF	splash10-0002-0900000000-456e1257123470a131c2	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF	splash10-0a4i-0190000000-0f4cf059747adb026b96	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF	splash10-0a4i-0090000000-ecaeebd63dc195659e57	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF	splash10-0002-0900000000-6da1a9a3edfed770c2cd	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF	splash10-00xs-0900000000-d71f5b857319380ce595	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF	splash10-01bc-2900000000-37eb3191934e545cc338	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF	splash10-014l-6900000000-6be893f7d4702639eac2	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF	splash10-0a4i-0190000000-c2030f3f981d83eacf57	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF	splash10-0a4i-0190000000-3c27da7fa8c958a76be1	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF	splash10-0002-0900000000-133c9cb2f2383aa0fe8a	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF	splash10-00r5-1900000000-b68a2013855cb02e4512	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF	splash10-01bd-1900000000-c4fd6863785e44cc724e	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF	splash10-014l-3900000000-4529fcb6c89f3acafac9	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF	splash10-0002-0900000000-06348bdc8d24fed52e75	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Atomoxetine , positive-QTOF	splash10-0a4i-0690000000-494128ae0f3b90b415b3	2017-09-14	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Atomoxetine 45V, Positive-QTOF	splash10-0002-0900000000-133c9cb2f2383aa0fe8a	2021-09-20	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Atomoxetine 30V, Positive-QTOF	splash10-0a4i-0190000000-3c27da7fa8c958a76be1	2021-09-20	HMDB team, MONA	View Spectrum
Experimental LC-MS/MS	LC-MS/MS Spectrum - Atomoxetine 45V, Positive-QTOF	splash10-0002-0900000000-6da1a9a3edfed770c2cd	2021-09-20	HMDB team, MONA	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - Atomoxetine 10V, Positive-QTOF	splash10-0a6r-0090000000-baa3d0729ad3bb59a89f	2016-08-01	Wishart Lab	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - Atomoxetine 20V, Positive-QTOF	splash10-054p-7690000000-47a6bba7ee3a8fb547e3	2016-08-01	Wishart Lab	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - Atomoxetine 40V, Positive-QTOF	splash10-0006-9400000000-2bb86246ec7cd0612674	2016-08-01	Wishart Lab	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - Atomoxetine 10V, Negative-QTOF	splash10-0udi-0090000000-02a8368dee3cab1e1702	2016-08-03	Wishart Lab	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - Atomoxetine 20V, Negative-QTOF	splash10-0udi-2290000000-6d5c426420a70e542e1c	2016-08-03	Wishart Lab	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - Atomoxetine 40V, Negative-QTOF	splash10-0a6r-9710000000-6adb2c5abb0cab9b62a8	2016-08-03	Wishart Lab	View Spectrum

Biological Properties

Cellular Locations

Membrane

Biospecimen Locations

Blood
Urine

Tissue Locations

Not Available

Pathways

Not Available

Name	SMPDB/PathBank	KEGG

Normal Concentrations

Biospecimen	Status	Value	Age	Sex	Condition	Reference	Details
Blood	Expected but not Quantified	Not Quantified	Not Available	Not Available	Taking drug identified by DrugBank entry DB00289	21059682	details
Urine	Expected but not Quantified	Not Quantified	Not Available	Not Available	Taking drug identified by DrugBank entry DB00289	21059682	details

Abnormal Concentrations

Not Available

Predicted Concentrations

Biospecimen	Value	Original age	Original sex	Original condition	Comments
Blood	0.000 uM	Adult (>18 years old)	Both	Normal	Predicted based on drug qualities
Blood	0.000 umol/mmol creatinine	Adult (>18 years old)	Both	Normal	Predicted based on drug qualities

Associated Disorders and Diseases

Disease References

None

Associated OMIM IDs

None

External Links

DrugBank ID

DB00289

Phenol Explorer Compound ID

Not Available

FooDB ID

Not Available

KNApSAcK ID

Not Available

Chemspider ID

49516

KEGG Compound ID

Not Available

BioCyc ID

Not Available

BiGG ID

Not Available

Wikipedia Link

Atomoxetine

METLIN ID

Not Available

PubChem Compound

54841

PDB ID

Not Available

ChEBI ID

127342

Food Biomarker Ontology

Not Available

VMH ID

Not Available

MarkerDB ID

Not Available

Good Scents ID

Not Available

References

Synthesis Reference

Not Available

Material Safety Data Sheet (MSDS)

Not Available

General References

Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP: [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents]. Encephale. 2005 May-Jun;31(3):337-48. [PubMed:16142049 ]
Gaillez C, Sorbara F, Perrin E: [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children]. Encephale. 2007 Sep;33(4 Pt 1):621-8. [PubMed:18033153 ]
Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, Sarkis EH, Wagner KD, Gao H, Michelson D, Biederman J: Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005 Sep;44(9):915-24. [PubMed:16113620 ]
Carpenter LL, Milosavljevic N, Schecter JM, Tyrka AR, Price LH: Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. J Clin Psychiatry. 2005 Oct;66(10):1234-8. [PubMed:16259536 ]
Pilhatsch MK, Burghardt R, Wandinger KP, Bauer M, Adli M: Augmentation with atomoxetine in treatment-resistant depression with psychotic features. A case report. Pharmacopsychiatry. 2006 Mar;39(2):79-80. [PubMed:16555170 ]
Spencer TJ, Faraone SV, Michelson D, Adler LA, Reimherr FW, Glatt SJ, Biederman J: Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. J Clin Psychiatry. 2006 Mar;67(3):415-20. [PubMed:16649828 ]
McElroy SL, Guerdjikova A, Kotwal R, Welge JA, Nelson EB, Lake KA, Keck PE Jr, Hudson JI: Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry. 2007 Mar;68(3):390-8. [PubMed:17388708 ]
Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo MJ, Alda JA, Gastaminza X, Garcia-Polavieja MJ, Gilaberte I, Escobar R: Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin. 2009 Nov;25(11):2745-54. doi: 10.1185/03007990903316152. [PubMed:19785510 ]

Enzymes

Enzyme Details

1. Cytochrome P450 3A4

General function:: Involved in monooxygenase activity
Specific function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide.
Gene Name:: CYP3A4
Uniprot ID:: P08684
Molecular weight:: 57255.585

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Enzyme Details

2. Cytochrome P450 2C19

General function:: Involved in monooxygenase activity
Specific function:: Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:: CYP2C19
Uniprot ID:: P33261
Molecular weight:: 55944.565

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Enzyme Details

3. Cytochrome P450 2D6

General function:: Involved in monooxygenase activity
Specific function:: Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:: CYP2D6
Uniprot ID:: P10635
Molecular weight:: 55768.94

References

Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP: [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents]. Encephale. 2005 May-Jun;31(3):337-48. [PubMed:16142049 ]
Garnock-Jones KP, Keating GM: Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. [PubMed:19445548 ]
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Enzyme Details

1. Sodium-dependent noradrenaline transporter

General function:: Involved in neurotransmitter:sodium symporter activity
Specific function:: Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:: SLC6A2
Uniprot ID:: P23975
Molecular weight:: 69331.42

References

Biederman J, Heiligenstein JH, Faries DE, Galil N, Dittmann R, Emslie GJ, Kratochvil CJ, Laws HF, Schuh KJ: Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics. 2002 Dec;110(6):e75. [PubMed:12456942 ]
Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ: Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002 Dec;63(12):1140-7. [PubMed:12523874 ]
Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D: Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003 Jan 15;53(2):112-20. [PubMed:12547466 ]
Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J: Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003;26(10):729-40. [PubMed:12862507 ]
Wernicke JF, Adler L, Spencer T, West SA, Allen AJ, Heiligenstein J, Milton D, Ruff D, Brown WJ, Kelsey D, Michelson D: Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol. 2004 Feb;24(1):30-5. [PubMed:14709944 ]
Garnock-Jones KP, Keating GM: Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. [PubMed:19445548 ]
Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF: Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord. 2004 Oct;8(2):45-52. [PubMed:15801334 ]
Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP: [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents]. Encephale. 2005 May-Jun;31(3):337-48. [PubMed:16142049 ]
Gaillez C, Sorbara F, Perrin E: [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children]. Encephale. 2007 Sep;33(4 Pt 1):621-8. [PubMed:18033153 ]
Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]

Enzyme Details

2. Sodium-dependent serotonin transporter

General function:: Involved in neurotransmitter:sodium symporter activity
Specific function:: Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin and recycles it in a sodium-dependent manner.
Gene Name:: SLC6A4
Uniprot ID:: P31645
Molecular weight:: 70324.165

References

Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]

Showing metabocard for Atomoxetine (HMDB0014434)

MOL for HMDB0014434 (Atomoxetine)

3D MOL for HMDB0014434 (Atomoxetine)

3D SDF for HMDB0014434 (Atomoxetine)

3D-SDF for HMDB0014434 (Atomoxetine)

PDB for HMDB0014434 (Atomoxetine)

3D PDB for HMDB0014434 (Atomoxetine)

SMILES for HMDB0014434 (Atomoxetine)

INCHI for HMDB0014434 (Atomoxetine)

Structure for HMDB0014434 (Atomoxetine)

3D Structure for HMDB0014434 (Atomoxetine)

Experimental Collision Cross Sections

Predicted Collision Cross Sections

Predicted Kovats Retention Indices

Underivatized

Derivatized

GC-MS Spectra

MS/MS Spectra

Enzymes

References

References

References

Transporters

References

References